11-17-06

				and Tradema	PTO/SB/21 (09-06 ved for use through 03/31/2007. OMB 0651-003 ark Office; U.S. DEPARTMENT OF COMMERCI
Under the Paperwort	k Reduction Act of 1995, no per	sons are required to res	Application		ation unless it displays a valid OMB control numbe
Т	RANSMITT	AL	Filing Date		July 28, 2006
	FORM				Joacim Elmén
			Art Unit	_	N/A
(to be us	ed for all correspondence afte	r initial filing)	Examiner N	lame	Not Yet Assigned
Total Numbe	r of Pages in This Submis	sion	Attorney Docket Number		er 66015(71432)
	EN	ICLOSURES	(Check all	that app	ly)
Fee Trans	mittal Form	Drawing(s)			After Allowance Communication to TC
Fee	Attached	Licensing-rel	ated Papers		Appeal Communication to Board of Appeals and Interferences
Amendme	nt/Reply	Petition			Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
After	Final	Petition to Convert to a Provisional Application			Proprietary Information
Affid		Power of Attorney, Revocation Change of Correspondence Address Status Lette		Status Letter	
Extension	of Time Request	Terminal Disc	claimer		X Other Enclosure(s) (please Identify below):
Express Al	bandonment Request	Request for	Refund		Return Receipt Postcard
x Information	n Disclosure Statement	CD, Number	of CD(s)		
Certified C	opy of Priority (s)	Landsc	ape Table on	CD	
	issing Parts/ Application	Remarks			
	y to Missing Parts under FR 1.52 or 1.53				
	1.10				
	SIGNATI	JRE OF APPLICA	NT, ATTOR	RNEY, OR	AGENT
Firm Name	EDWARDS ANGEL	PALMER & DO	DGE LLP		
Signature	Chric	ch			
Printed name	Christine C. O'Day				
Date	November 15, 2006			Reg. No.	38,256

Express Mail, Label No. EV 971 786 911 U	ny paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as S, on the date shown below in an envelope addressed to:
Dated: November 15, 2006	, P.O. Box 1450(Alexandria, VA ,22318)1450. Signature: CHILDENT JUNKLL (Elisabeth Dunkle)

Application No. (if known): 10/587,775

Attorney Docket No.: 66015(71432)

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV 971 786 911 US in an envelope addressed to:

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on	November 15, 2006
	Date

Cluabeth	Dunkle
Signat	ure
Elisabeth	Dunkle
Typed or printed name of p	erson signing Certificate
	(617) 439-4444
Registration Number, if applicable	Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Transmittal (1 page)

Information Disclosure Statement (2 pages)

IDS (Citation) by Applicant (38 References) (3 pages)



I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Label No. EV 971 786 911 US, on the date shown below in an envelope addressed to: MS Amendment, Commissioneyror Patents, P.O. Box 1450, Alexandria. VA 22313-1450.

Dated: November 15, 2006 Signature: Quality (1911)

Docket No.: 66015(71432) (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Joacim Elmén et al.

Application No.: 10/587,775

Confirmation No.:

Filed: July 28, 2006

Art Unit: N/A

For:

MODIFIED SHORT INTERFERING RNA

(MODIFIED SIRNA)

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be

an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 66015(71432). A duplicate copy of this paper is enclosed.

Dated: November 15, 2006

Respectfully submitted,

Christine C. O'Day

Registration No.: 38,256

hit Ch

EDWARDS ANGELL PALMER & DODGE

LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Attorneys/Agents For Applicant

PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known					
Application Number	10/587,775				
Filing Date	July 28, 2006				
First Named Inventor	Joacim Elmén				
Art Unit	N/A				
Examiner Name	Not Yet Assigned				
Attorney Docket Number	66015(71432)				

Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-10/552,152			

	FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages			
Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	T⁵		
	BA	WO-03/070918 A2	08-28-2003					
	BB	WO-2004/099378 A2	11-18-2004					
	BC	WO-99/14226	03-25-1999	1				
	BD WO-00/56746		09-28-2000					
	BE WO-00/56748		09-28-2000					
	BF WO-01/25248 A2		04-12-2001			\Box		
	BG	WO-03/006475 A2	01-23-2003			\Box		
	BH WO-02/28875 A2		04-11-2002					
	ВІ	WO-03/095467 A1	11-20-2003					
	BJ	WO-2004/042046 A2	05-21-2004			\Box		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	D. Braasch et al., "RNA Interference in Mammalian Cells by Chemically-Modified RNA", Biochem., Vol. 42, No. 26, pp. 7967-7975 (2003)	
	СВ	S. Parrish et al., "Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference", Mol. Cell, Vol. 6, pp. 1077-1087 (2000)	
	CC	A. Fire et al., "Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans", Nature, Vol. 391, pp. 806-811 (1998)	
	CD	A. Fire, "RNA-triggered gene silencing", TIG, Vol. 15, No. 9, pp. 358-363 (1999)	
	CE	J. Bosher et al., "RNA interference: genetic wand and genetic watchdog", Nat. Cell Bio., Vol. 2 pp. E-31-E36 (2000)	
,	CF	A. Wargelius et al., "Double-Stranded RNA Induces Specific Developmental Defects in Zebrafish Embryos", Biochem. Biophys. Res. Com., Vol. 263, pp. 156-161 (1999)	
	CG	F. Wianny et al., "Specific interference with gene function by double-stranded RNA in early mouse development", Nat. Cell Biol., Vol. 2, pp. 70-75 (2000)	
	СН	L. Alexopoulou et al., "Recognition of double-stranded RNA and activation of NF-kB by Toll-like receptor 3", Nature, Vol. 413, pp. 732-738 (2001)	
	CI	G. Stark et al., "How Cells Respond to Interferons", Annu. Rev. Biochem., Vol. 67, pp. 227-264	

Examiner	Date
Signature	Considered

57467

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sut	estitute for form 1449/PTO			Complete if Known		
				Application Number	10/587,775	
l IN	IFORMATION	N DI	SCLOSURE	Filing Date	July 28, 2006	
S	TATEMENT I	BY A	APPLICANT	First Named Inventor	Joacim Elmén	
				Art Unit	N/A	
	(Use as many sh	eets as	s necessary)	Examiner Name	Not Yet Assigned	
Sheet	Sheet 2 of 3		Attorney Docket Number	66015(71432)		

	(1998)	Γ
Cl	C. Samuel, "Antiviral Actions of Interferons", Clin. Micro. Rev., Vol. 14, No. 4, pp. 778-809 (2001)	
СК	P. Zamore et al., "RNAi: Double-Stranded RNA Directs the ATP-Dependant Cleavage of mRNA at 21 to 23 Nucleotide Intervals", Cell, Vol. 101, pp. 25-33 (2000)	
CL	S. Elbashir et al., "RNA interference is mediated by 21- and 22-nucleotide RNAs", Gen. & Dev., Vol. 15, pp. 188-200 (2001)	
СМ	S. Elbashir et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells", Nature, Vol. 411, pp. 494-498 (2001)	
CN	M. McManus et al., "Gene Silencing in Mammals by Small Interfering RNAs", Nature Reviews Gen., Vol. 3, pp. 737-747 (2002)	
СО	S. Parrish et al., "Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference", Mol. Cell, Vol. 6, pp. 1077-1087 (2000)	
СР	A. Boutla et al., "Short 5'-phosphorylated double-stranded RNAs induce RNA interference in <i>Drosophila</i> ", Curr. Biol., Vol. 11, pp. 1776-1780 (2001)	
CQ	S. Elbashir et al., "Functional anatomy of siRNAs for mediating efficient RNAi in <i>Drosophila melanogaster</i> embryo lysate", The EMBO Journ., Vol. 20, No. 23, pp. 6877-6888 (2001)	
CR	T. Holen et al., "Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor", Nuc. Acids Res., Vol. 30, No. 8, pp. 1757-1766 (2002)	
cs	H. Hohjoh, "RNA interference (RNAi) induction with various types of synthetic oligonucleotide duplexes in cultured human cells", FEBS Lett., 521, pp. 195-199 (2002)	
СТ	M. Hamada et al., "Effects on RNA Interference in Gene Expression (RNAi) in Cultured Mammalian Cells of Mismatches and the Introduction of Chemical Modifications at the 3'-Ends of siRNAs", AntiSense and Nuc. Acid Drug Dev., Vol. 12, pp. 301-309 (2002)	
CU	A. Nykanen et al., "ATP Requirements and Small Interfering RNA Structure in the RNA Interference Pathway", Cell, Vol. 107, pp. 309-321 (2001)	
CV	J. Martinez et al., "Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi", Cell, Vol. 110, pp. 563-574 (2002)	
CW	S. Hammond et al., "An RNA-directed nuclease mediates post-transcriptional gene silencing in <i>Drosophila</i> cells", Nature, Vol. 404, pp. 293-296 (2000)	
СХ	M. Amarzguioui et al., "Tolerance for mutations and chemical modifications in a siRNA", Nuc. Acids Res., Vol. 31, No. 2, pp. 589-595 (2003)	_
CY	D. Braasch et al., "RNA Interference in Mammalian Cells by Chemically-Modified RNA", Biochem., Vol. 42, pp. 7967-7975 (2003)	
CZ	D. Braasch et al., "Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression", Biochem., Vol. 41, No. 14, pp. 4503-4510 (2002)	
CA1	Y. Hayakawa, "Toward an Ideal Synthesis of Oligonucleotides: Development of a Novel Phosphoramidite Method with High Capability", Bull. Chem. Soc. Jpn., Vol. 74, pp. 1547-1565 (2001)	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date
Signature	Considered

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.